NCT06032000View on ClinicalTrials.gov

Evaluation of Safety and Immunogenicity of a SARS-CoV-2(Severe Acute Respiratory Syndrome Coronavirus 2) Booster Vaccine (LEM-mR203)

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 6, 2023

Primary Completion Date

March 28, 2025

Study Completion Date

March 28, 2025

Conditions
COVID-19 InfectionCOVID-19 Vaccine Adverse Reaction
Interventions
BIOLOGICAL

LEM-mR203

mRNA vaccine using Lemonex's Drug Delivery System (DDS), DegradaBALL

BIOLOGICAL

Placebo

0.9% Sodium Chloride Solution

Trial Locations (1)

03080

Seoul National University Hospital Clinical Trials Center, Seoul

Sponsors

Lead Sponsor

Lemonex
All Listed Sponsors
lead

Lemonex

INDUSTRY